Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2004 1
2005 1
2012 1
2014 1
2015 1
2018 1
2019 2
2020 3
2021 2
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Osonoi T, Saito M, Hosoya M, Douguchi S, Ofuchi K, Katoh M. Osonoi T, et al. Among authors: katoh m. Front Endocrinol (Lausanne). 2023 Jan 11;13:1042061. doi: 10.3389/fendo.2022.1042061. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36714585 Free PMC article.
Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
Osonoi T, Shirabe S, Saito M, Hosoya M, Douguchi S, Ofuchi K, Katoh M. Osonoi T, et al. Among authors: katoh m. Front Pharmacol. 2023 Jun 7;14:1205021. doi: 10.3389/fphar.2023.1205021. eCollection 2023. Front Pharmacol. 2023. PMID: 37351507 Free PMC article.
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
Iijima T, Katoh M, Takedomi K, Yamamoto Y, Akatsuka H, Shirata N, Nishi A, Takakuwa M, Watanabe Y, Munakata H, Koyama N, Ikeda T, Iguchi T, Kato H, Kikkawa K, Kawaguchi T. Iijima T, et al. Among authors: katoh m. J Med Chem. 2022 Jun 23;65(12):8127-8143. doi: 10.1021/acs.jmedchem.2c00402. Epub 2022 Jun 2. J Med Chem. 2022. PMID: 35652647
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
Iwaki Y, Ohhata A, Nakatani S, Hisaichi K, Okabe Y, Hiramatsu A, Watanabe T, Yamamoto S, Nishiyama T, Kobayashi J, Hirooka Y, Moriguchi H, Maeda T, Katoh M, Komichi Y, Ota H, Matsumura N, Okada M, Sugiyama T, Saga H, Imagawa A. Iwaki Y, et al. Among authors: katoh m. ACS Med Chem Lett. 2020 May 14;11(6):1335-1341. doi: 10.1021/acsmedchemlett.0c00200. eCollection 2020 Jun 11. ACS Med Chem Lett. 2020. PMID: 32551021 Free PMC article.
Synergistic Effect of Motivation for the Elderly and Support for Going Out II: Measures to Induce Elderly Men to Go Out.
Tsutsui K, Ukita S, Kondo M, Toshima G, Miyazaki N, Nagashima K, Ohmura M, Tsuchihashi S, Tsuji Y, Katoh M, Aida N, Kobayashi Y, Ohtsu Y, Fujita Y, Tanaka S, Watanabe H, Naruse Y, Iizuka I, Kato H, Mashimo Y, Senbonmatsu T. Tsutsui K, et al. Among authors: katoh m. Geriatrics (Basel). 2024 Feb 18;9(1):21. doi: 10.3390/geriatrics9010021. Geriatrics (Basel). 2024. PMID: 38392108 Free article.
22 results